Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty [Yahoo! Finance]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Yahoo! Finance
Warning! GuruFocus has detected 6 Warning Signs with EDIT. With the next program update planned in the first quarter of 2025, the investment company highlighted Editas has now turned its attention to in vivo editing for treating sickle cell illness and beta thalassemia. Although this technique might provide a safety benefit by maybe removing the requirement for myeloablative conditioning, Raymond James voiced doubts regarding its effectiveness relative to the approved ex vivo technique. The company also underlined that Editas is trying to out-license its reni-cel treatment, a procedure it described as difficult given the low commercialization of rival treatments. Particularly, Vertex Pharmaceuticals ( VRTX Financials ) and CRISpen Therapeutics ( CRSP Financials ) have created a competing treatment called Casgevy with revised sales projections shortly. New results from a Phase 1/2/3 study of reni-cel is slated to be presented at the American Society of Hematology meeting from De
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- MCK Stock Down Despite Latest Partnership to Boost SCD Treatment [Yahoo! Finance]Yahoo! Finance
- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell? [Yahoo! Finance]Yahoo! Finance
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 48% Below Their Intrinsic Value Estimate [Yahoo! Finance]Yahoo! Finance
- SpyGlass Pharma Completes Enrollment in Phase I/II Study of its Promising Long-Term Drug Delivery Platform for Glaucoma and Ocular Hypertension [Yahoo! Finance]Yahoo! Finance
VRTX
Earnings
- 11/4/24 - Beat
VRTX
Sec Filings
- 11/19/24 - Form 4
- 11/15/24 - Form 144
- 11/13/24 - Form 4
- VRTX's page on the SEC website